24/7 Market News Snapshot 02 June, 2025 – Theravance Biopharma, Inc. (NASDAQ:TBPH)

June 2, 2025

DENVER, Colo., 02 June, 2025 (www.247marketnews.com) – (NASDAQ:TBPH) are discussed in this article.
Theravance Biopharma, Inc. has experienced notable momentum in the market, with shares opening at $10.00 and currently trading at $10.77, a remarkable increase of 17.58% following a close of $9.16 in the previous session. The trading volume has reached 506.94K, indicating substantial investor activity. Analysts note the stock has broken through critical resistance levels, with support near the $9.00 mark. Should this upward trend continue, targets may be established at $11.50, although potential overbought conditions warrant close observation for a possible price correction in forthcoming sessions.

In addition to the robust market performance, Theravance Biopharma has secured a transformative agreement that involves a one-time cash payment of $225 million. This deal represents a strategic initiative to enhance shareholder value and strengthen financial flexibility. The company has sold its remaining royalty interests in Trelegy Ellipta, a prominent respiratory treatment product, to Royalty Pharma. This transaction complements a prior $1.1 billion upfront payment received in 2022 and includes the possibility of additional milestone payments up to $200 million, bringing the total potential value derived from Trelegy Ellipta to approximately $1.525 billion.

CEO Rick E Winningham expressed confidence in the agreement, emphasizing its commitment to delivering immediate value to shareholders. While Theravance will not receive future royalties from Trelegy, it maintains eligibility for milestone payments in 2025 and 2026 based on specific sales targets. This decision stems from a comprehensive review by the Strategic Review Committee, with ongoing evaluations aimed at value enhancement.

As Theravance Biopharma progresses with its clinical pipeline, including YUPELRI and investigational product ampreloxetine, the company remains dedicated to disciplined capital strategies and optimizing shareholder returns. The Board is committed to exploring further opportunities to enrich shareholder value as the company continues to lead in innovative treatments that significantly improve patient health outcomes.

Related news for (TBPH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.